Zhengye Biotechnology Holding Limited (ZYBT) Earnings History
Annual and quarterly earnings data from 2021 to 2024
Loading earnings history...
ZYBT EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
ZYBT Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 49.0% | 8.8% | 6.1% |
| 2023 | 61.4% | 21.3% | 14.9% |
| 2022 | 59.0% | 25.3% | 18.0% |
| 2021 | 58.6% | 24.5% | 18.2% |
Download Data
Export ZYBT earnings history in CSV or JSON format
Free sign-in required to download data
Zhengye Biotechnology Holding Limited (ZYBT) Earnings Overview
As of May 8, 2026, Zhengye Biotechnology Holding Limited (ZYBT) reported trailing twelve-month net income of $11M. The company earned $0.00 per diluted share over the past four quarters, with a net profit margin of 6.1%.
Looking at the long-term picture, ZYBT's historical earnings data spans multiple years. The company achieved its highest annual net income of $47M in fiscal 2022.
Zhengye Biotechnology Holding Limited maintains positive profitability with a gross margin of 49.0%, operating margin of 8.8%, and net margin of 6.1%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including ATXG (-$7M net income, -121.8% margin), CLPS (-$4M net income, -4.3% margin), TAOP (-$7M net income, -32.7% margin), ZYBT has outperformed on profitability metrics. Compare ZYBT vs ATXG →
ZYBT Earnings vs Peers
Earnings metrics vs comparable public companies
ZYBT Historical Earnings Data (2021–2024)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $11M | -64.0% | $16M | $0.00 | 6.1% | 8.8% |
| 2023 | $31M | -32.7% | $45M | $0.00 | 14.9% | 21.3% |
| 2022 | $47M | +20.0% | $66M | $0.00 | 18.0% | 25.3% |
| 2021 | $39M | - | $52M | $0.00 | 18.2% | 24.5% |
See ZYBT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ZYBT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ZYBT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonZYBT — Frequently Asked Questions
Quick answers to the most common questions about buying ZYBT stock.
Is ZYBT growing earnings?
ZYBT TTM EPS: $0.00. Net income: $11M. Earnings growth: N/A.
What are ZYBT's profit margins?
Zhengye Biotechnology Holding Limited net margin is +6.1%, with operating margin at +8.8%. Margins sit within typical range for the sector.
How consistent are ZYBT's earnings?
ZYBT earnings data spans 2021-2024. The current earnings trend is N/A YoY. Historical data enables comparison across business cycles.